Dottikon ES Holding AG (Dottikon) is a Swiss specialty chemical and pharmaceutical manufacturing group that develops and produces high-value chemical intermediates, exclusive small molecule active pharmaceutical ingredients (APIs), and performance chemicals for chemical, biotech, and pharmaceutical customers. The company differentiates through expertise in hazardous reactions and advanced process technologies (including low temperature and high pressure chemistry and continuous processing). It's one site strategy at an integrated facility that supports efficient decision-making, close customer interaction, and fast scale-up from kilogram quantities to multi-ton commercial volumes, with a strong focus on safety, reliability, quality, flexibility, and speed.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Dottikon has undertaken several R&D initiatives focused on the development and optimization of chemical processes and technical manufacturing procedures. The company aims to improve selectivities, yields, and purities while reducing energy consumption, waste, and CO2 emissions. The R&D unit of the company is part of the Processes & Technologies department, which is responsible for designing, developing, and optimizing chemical processes for rapid scale-up from kilograms to multi-tons. In FY2025, the company incurred R&D expenses of CHF22.10 million, which stood at 5.7% of the company’s revenue.